The IPM Alliance welcomes the G7 Leaders’ Call on the fight against cancer as a timely and powerful signal that cancer policy must now move decisively from ambition to implementation.
The G7 statement places cancer where it belongs: at the centre of health-system resilience, innovation policy and global equity. With cancer killing nearly 10 million people each year, and new cases projected to rise by 80% globally by 2050, the message is clear. Incremental change will not be enough.
Prevention, screening, earlier diagnosis, access to quality care, research collaboration, data use and faster translation of innovation into clinical practice must become core pillars of modern cancer policy.
For IPM Alliance, the most important feature of the G7 call is its direct alignment with the delivery logic of personalised medicine. The statement highlights international scientific cooperation, interoperable data standards, responsible cross-border data collaboration, clinical, genomic and imaging data, artificial intelligence, improved clinical decision-making and faster adoption of innovation.
That is exactly the agenda patients and health systems now need.
This is not abstract. It is about ensuring that the right patient receives the right intervention at the right time, supported by the right diagnostic, data and clinical infrastructure.
This week in Nice, IPM Alliance has been engaging on many of these same questions: how Europe and its partners can embed precision oncology, molecular diagnostics, AI-enabled decision support, clinical trial access and cross-border learning into routine care. These are also the issues IPM Alliance has advanced through recent discussions with leaders and stakeholders across several regions, from ASCO to Brussels to China.
A clear international consensus is emerging: personalised medicine cannot remain a policy aspiration. It must become an implementation agenda.
That momentum is further strengthened by the World Health Assembly resolution on precision medicine, endorsed on 22 May 2026. The resolution recognises precision medicine as a pathway towards targeted, personalised and equitable care. It calls for national policies, infrastructure, workforce capacity, governance, affordability, inclusive research, regulation and data frameworks to support responsible implementation.
Taken together, the G7 cancer call and the WHA precision medicine resolution create a critical policy window. They connect cancer control with the broader transformation of health systems. They also make clear that equity must be built in from the start.
Without deliberate action, innovation can widen disparities. With the right frameworks, it can close them.
IPM Alliance will build on this momentum.
We will continue working with policymakers, patient organisations, clinicians, researchers, industry and health-system leaders to turn these commitments into practical action. That means supporting readiness for molecular diagnostics, promoting interoperable and trustworthy health data systems, strengthening access to clinical trials, advancing precision oncology, and ensuring that innovation reaches patients across countries and regions, not only in centres of excellence.
The political signal is now unmistakable. The task ahead is delivery.
IPM Alliance stands ready to contribute to that delivery agenda: from declarations to implementation, from innovation to access, and from cancer ambition to measurable patient benefit.
